
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Click the blue words to follow us






Joy
Report
Come
Lin
According to the Regulations on the Administration of the Identification of High-tech Enterprises (Guo Ke Fa Huo [2016] No. 32) and the Guidelines for the Administration of the Identification of High-tech Enterprises (Guo Ke Fa Huo [2016] No. 195), the Office of the National Leading Group for the Identification and Administration of High-tech Enterprises announces the second batch of 4,736 high-tech enterprises identified and reported by the Shanghai Identification Agency in 2025 for record-keeping (see attachment for details).ShineyoMedicalShineyoMedical Officially Passes the Certification of "National High-tech Enterprise" (Attachment List Serial Number 789)。

"The National High-tech Enterprise" qualification is one of the highest-level certifications that a technology-based enterprise in China can obtain, jointly reviewed and granted by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation. This certification sets strict high standards for the company’s core independent intellectual property rights, R&D team strength, efficiency of technology transfer, and organizational management level.

The successful evaluation of ShineyoMedical as a high-tech enterprise marks that the company meets the mandatory requirements set by relevant national, provincial, and municipal departments in terms of technological innovation, intellectual property, transformation of scientific and technological achievements, management level of research and development organization, and business performance.Has obtained national authoritative recognition,Becoming an important milestone on the company's path to growth.
ShineyoMedical, as a company that has regarded technological innovation as a differentiated competitive advantage since its establishment, has always focused on scientific and technological innovation and the development of independent intellectual property rights. This successful evaluation is not only a recognition of ShineyoMedical's overall technical level but also a responsibility and an encouragement. In the future, ShineyoMedical will continue to strengthen the transformation of new technology achievements and the construction of independent innovation capabilities. Against the backdrop of rapid development in industry informatization and new technologies, the company will continuously consolidate its core competitiveness and is committed to providing lasting and strong support for the informatization development in the medical field.

ShineyoMedical RhythPulse®-PFA System
ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal, and targeted ablation, primarily used for treating drug-refractory and recurrent atrial fibrillation and other rapid arrhythmias. Its core advantages include:
Large Focal Spot Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, increasing the ablation efficiency by more than three times compared to traditional technology.
Targeted Ablation Technology:Equipped with an intelligent contact detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.
Clinical Validation Excellent:In a clinical trial involving 151 cases, the immediate success rate was 100%, and the success rate for atrial fibrillation treatment at 12 months post-operation reached 85.07%, achieving internationally leading standards.


High-tech Enterprise
WeChat ID丨ShineyoMedical
Official Website丨shineyomedical.com
